Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBL0137 in Previously Treated Hematological Cancers
NCT02931110Phase 1Terminated
- Sponsor
- Incuron
- Start
- Jan 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cbl0137 in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 6 more, sponsored by Incuron. Primary endpoints: Maximum Tolerated Dose, Recommended Dose and 1 more. Started Jan 2017; status: terminated.
02
Drugs
cbl0137
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)Hodgkin lymphoma (HL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02931110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931110.